AER 1517206 was received on 05/Jan/2015, received from a physician via AEMPS (Spain, 
ESAGEMED505187233) and concerns a 50 years old female patient who developed progressive multifocal 
leukoencephalopathy while being treated with rituximab (Mabthera). 
No medical history, concurrent conditions, concomitant medications or past drugs were reported. 
On 14/Jul/2011, the patient started therapy with intravenous drip rituximab (11 g every 6 months) for polymyositis. 
On 06/Sep/2013, she received the most recent dose of rituximab.  Later in 2013, she developed progressive 
multifocal leukoencephalopathy and hospitalised. The John Cunningham (JC) serology viral load was negative.
At the time of report, the outcome of progressive multifocal leukoencephalopathy was unknown. Therapy with 
rituximab was discontinued. 
Print Time: 26-MAY-2016 01:56 PM If a field is blank, there is no data for that field Page 304 of 675
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The reporter did not assessed the causal relationship for progressive multifocal leuko encephalopathy with 
rituximab.
No further information was provided.